Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEP-IV is a small molecule belonging to the dioxathiadiaza-heteropentalene class. It functions as an antimicrobial agent by inhibiting the growth of *Escherichia coli*. Its mechanism involves being reduced within the bacterial cell and subsequently reoxidized by molecular oxygen, a process that generates toxic reactive oxygen species, specifically superoxide (O2-) and hydrogen peroxide (H2O2). The toxicity of HEP-IV is dependent on the presence of oxygen and can be counteracted by cellular defenses such as superoxide dismutase (SOD) and catalase, which are induced by substances like yeast extract. Among its related compounds (HEP-I, HEP-II, HEP-III), HEP-IV demonstrates the highest potency in both inhibiting *E. coli* growth and inducing these protective enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HEP-IV.